Keymed Biosciences, Inc. (2162) Income Statement

1 Followers

Keymed Biosciences, Inc. Income Statement

Last quarter (Q4 2025), Keymed Biosciences, Inc.'s total revenue was ¥213.93M, an increase of 693.19% from the same quarter last year. In Q4, Keymed Biosciences, Inc.'s net income was ¥-436.39M. See Keymed Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Total Revenue	¥ 697.77M	¥ 428.12M	¥ 354.10M	¥ 100.06M	¥ 110.27M
Gross Profit	¥ 516.51M	¥ 415.92M	¥ 317.22M	¥ 97.48M	¥ 93.07M
Operating Expenses	¥ 1.10B	¥ 1.03B	¥ 752.02M	¥ 641.29M	¥ 450.61M
Depreciation and Amortization	¥ 95.49M	¥ 51.63M	¥ 69.16M	¥ 36.12M	¥ 21.02M
EBITDA	¥ -489.36M	¥ -574.46M	¥ -269.77M	¥ -259.25M	¥ -3.86B
Operating Income	¥ -584.85M	¥ -618.10M	¥ -434.80M	¥ -543.81M	¥ -3.88B
Other Income/Expenses	¥ 77.61M	¥ 109.45M	¥ 78.61M	¥ 240.21M	¥ -3.52B
Pretax Income	¥ -507.25M	¥ -508.65M	¥ -356.19M	¥ -303.60M	¥ -3.89B
Net Income	¥ -509.11M	¥ -515.24M	¥ -359.36M	¥ -308.12M	¥ -3.90B
Per Share Metrics
Basic EPS	¥ -1.86	¥ -1.97	¥ -1.37	¥ -1.18	¥ -24.24
Diluted EPS	¥ -1.86	¥ -1.97	¥ -1.37	¥ -1.18	¥ -24.24
Weighted Average Shares Outstanding	273.98M	261.95M	261.37M	261.13M	160.85M
Weighted Average Shares Outstanding (Diluted)	273.98M	261.95M	261.37M	261.13M	160.85M

Currency in CNY

Keymed Biosciences, Inc. (2162) Income Statement

Keymed Biosciences, Inc. Income Statement

Keymed Biosciences, Inc. Earnings and Revenue History